Write in a clean editor, then format for ACS Infectious Diseases in one click — DocuGuru applies the official American Chemical Society template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
ACS Infectious Diseases is a peer-reviewed journal published by American Chemical Society, covering Antibiotic Resistance in Bacteria, Antimicrobial Peptides and Activities, Tuberculosis Research and Epidemiology. Over its lifetime it has published 2,832 papers, which have received 55,991 citations.
| Publisher | American Chemical Society |
|---|---|
| Reference style | Superscript numbered (ACS) Superscript — small raised numerals in the text (1) Smith, A.; Jones, B.; Lee, C. A Representative Article Title. ACS Infectious Diseases 2023, 12, 45–58.
Formats any DOI in ACS Infectious Diseases style. No sign-up. |
| Publishes research in | Antibiotic Resistance in Bacteria Antimicrobial Peptides and Activities Tuberculosis Research and Epidemiology Academic Writing and Publishing Bacterial biofilms and quorum sensing |
| ISSN | 2373-8227 |
| Citation impact (2-yr) | 4.34 |
| h-index | 90 |
| i10-index | 1,400 |
| Top institutions publishing here | Centre National de la Recherche Scientifique |
| Journal website | pubs.acs.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Quaternary ammonium compounds (QACs) have represented one of the most visible and effective classes of disinfectants for nearly a century. With simple preparation, wide structural variety, and versatile incorporation into consumer products, there have been manifold developments and applications of these structures. Generally operating via disruption of one of the most fundamental structures in bacteria-the…
Gram-negative bacteria are intrinsically resistant to many antibiotics. Species that have acquired multidrug resistance and cause infections that are effectively untreatable present a serious threat to public health. The problem is broadly recognized and tackled at both the fundamental and applied levels. This paper summarizes current advances in understanding the molecular bases of the low…
Antiviral therapeutics with profiles of high potency, low resistance, panserotype, and low toxicity remain challenging, and obtaining such agents continues to be an active area of therapeutic development. Due to their unique three-dimensional structural features, spirooxindoles have been identified as privileged chemotypes for antiviral drug development. Among them, spiro-pyrazolopyridone oxindoles have been recently reported as…
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an…
Severe acute respiratory syndrome (SARS) is caused by a coronavirus (SARS-CoV) and has the potential to threaten global public health and socioeconomic stability. Evidence of antibody-dependent enhancement (ADE) of SARS-CoV infection in vitro and in non-human primates clouds the prospects for a safe vaccine. Using antibodies from SARS patients, we identified and characterized SARS-CoV B-cell…
